Abstract
Surgery remains the mainstay of melanoma therapy at all sites. Melanoma is widely believed to be a radioresistant tumor, a misconception that has historically led to the limited use of RT for its treatment. We searched pubmed from 1978 until 2010 by means of prospective randomized trials. The aim was to assess the potential impact of radiotherapy (RT) on local control, quality of life and overall survival. Radiotherapy should be considered in lentigo maligna, especially in elderly patients with extensive or unresectable disease in difficult areas on the face, with adequate tumor control with good cosmetic and functional results. In addition, radiation therapy provides effective palliation in patients with metastatic malignant melanoma. Doses up to 30 Gy or BED > 39.0Gy were found to be associated with prolonged palliation. These findings should be viewed with caution because the lack of data regarding performance status as well as other unknown confounding factors limits the applicability of retrospectives studies. We recommend that higher doses of RT be considered when using RT for the palliation of patients with metastatic melanoma and a performance status that could tolerate such therapy. In the futute, the combination of radiation therapy with hyperthermia may be a reasonable therapeutic option.
Keywords: Melanoma, radiotherapy, hyperthermia, review
Reviews on Recent Clinical Trials
Title: Melanoma: The Radiotherapeutic Point of View; Review of the Current Literature
Volume: 6 Issue: 2
Author(s): Zygogianni A., Kyrgias G., Kouvaris J., Mystakidou K., Gogas H. and Kouloulias V.
Affiliation:
Keywords: Melanoma, radiotherapy, hyperthermia, review
Abstract: Surgery remains the mainstay of melanoma therapy at all sites. Melanoma is widely believed to be a radioresistant tumor, a misconception that has historically led to the limited use of RT for its treatment. We searched pubmed from 1978 until 2010 by means of prospective randomized trials. The aim was to assess the potential impact of radiotherapy (RT) on local control, quality of life and overall survival. Radiotherapy should be considered in lentigo maligna, especially in elderly patients with extensive or unresectable disease in difficult areas on the face, with adequate tumor control with good cosmetic and functional results. In addition, radiation therapy provides effective palliation in patients with metastatic malignant melanoma. Doses up to 30 Gy or BED > 39.0Gy were found to be associated with prolonged palliation. These findings should be viewed with caution because the lack of data regarding performance status as well as other unknown confounding factors limits the applicability of retrospectives studies. We recommend that higher doses of RT be considered when using RT for the palliation of patients with metastatic melanoma and a performance status that could tolerate such therapy. In the futute, the combination of radiation therapy with hyperthermia may be a reasonable therapeutic option.
Export Options
About this article
Cite this article as:
A. Zygogianni, G. Kyrgias, J. Kouvaris, K. Mystakidou, H. Gogas and V. Kouloulias, Melanoma: The Radiotherapeutic Point of View; Review of the Current Literature, Reviews on Recent Clinical Trials 2011; 6 (2) . https://dx.doi.org/10.2174/157488711795177877
DOI https://dx.doi.org/10.2174/157488711795177877 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Single Nucleotide Polymorphisms as the Efficient Prognostic Markers in Breast Cancer
Current Cancer Drug Targets Triggering PIK3CA Mutations in PI3K/Akt/mTOR Axis: Exploration of Newer Inhibitors and Rational Preventive Strategies
Current Pharmaceutical Design AIDS Related Viruses, their Association with Leukemia, and Raf Signaling
Current HIV Research Nitric Oxide and Cancer Therapy: The Emperor has NO Clothes
Current Pharmaceutical Design Therapeutic Vaccines Explored in Patients with Non-Small Cell Lung Cancer
Anti-Cancer Agents in Medicinal Chemistry Pregnancy and Postpartum Influences on Rheumatoid Arthritis Activity:Natures Model to Investigate Systemic Biological Mechanisms in the Disease
Current Rheumatology Reviews Formulation and Characterization of Rutin Loaded Chitosan-alginate Nanoparticles: Antidiabetic and Cytotoxicity Studies
Current Drug Delivery Factors Affecting Quantification in PET/CT Imaging
Current Medical Imaging Impact of PET on the Radiation Treatment of Hodgkins Lymphoma
Current Radiopharmaceuticals Resistance to Chemotherapy and Molecularly Targeted Therapies: Rationale for Combination Therapy in Malignant Melanoma
Current Molecular Medicine Antihyperlipidemic and Antiobesity Potential of <i>Aquilaria agallocha</i> and <i>Borago officinalis</i> in Fixed-Dose Combination; A Contingent Probe with Atorvastatin and Orlistat
Current Bioactive Compounds Novel Superactive Leptin Antagonists and their Potential Therapeutic Applications
Current Pharmaceutical Design Vitamin D Affects the Warburg Effect and Stemness Maintenance of Non- Small-Cell Lung Cancer Cells by Regulating the PI3K/AKT/mTOR Signaling Pathway
Current Cancer Drug Targets Natural Products and Transforming Growth Factor-beta (TGF-β) Signaling in Cancer Development and Progression
Current Cancer Drug Targets DYRK1A Kinase Inhibitors with Emphasis on Cancer
Mini-Reviews in Medicinal Chemistry Preface
Current Cancer Drug Targets Artificial Sun Protection: Sunscreens and Their Carrier Systems
Current Drug Delivery Role of Dietary Xenobiotics-Gene Interactions in Carcinogenesis: Protective Effects of Nutritional Factors
Current Nutrition & Food Science Androgen Receptor Cofactors in Prostate Cancer: Potential Therapeutic Targets of Castration-Resistant Prostate Cancer
Current Cancer Drug Targets Scutellarin Suppresses RPMI7951 Melanoma Cell Proliferation by Targeting TOPK
Anti-Cancer Agents in Medicinal Chemistry